ABSTRACT
Results

Endotracheal placement of the balloon was successfully performed in all 21 cases and the mean duration of the operation was 20
 (range, 5-54) 
INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a sporadic defect with a birth prevalence of approximately 1 in 4000.
In about 30% of affected fetuses there are associated chromosomal abnormalities or other defects. In those fetuses with isolated CDH, survival after postnatal surgery is about 50%, but the remainder die due to pulmonary hypoplasia and pulmonary hypertension. Some reports suggest that higher survival rates may be achieved with improved postnatal care. However, this apparent improvement may be a mere consequence of case selection bias due to termination of the more severely affected fetuses 1 . Lethal pulmonary hypoplasia may be predicted prenatally by the sonographic finding of a fetal lung area to head circumference ratio (LHR) < 1 in the presence of liver herniation 2 -6 . Extensive animal studies have demonstrated that pulmonary hypoplasia and hypertension are reversible by intrauterine anatomical repair to restore the herniated viscera back to the abdomen. In a few cases of human CDH, hysterotomy and fetal surgery have been carried out but this intervention has now been abandoned because it was associated with a high maternal morbidity and did not demonstrate improved fetal survival 7 . Furthermore, the operation cannot be performed in fetuses with liver herniation (the group most likely to benefit from prenatal surgery) because intraoperative reduction of the liver to the abdomen leads to kinking of the umbilical vein.
Animal studies have shown that obstruction of the trachea, which results in expansion of the fetal lungs by retained pulmonary secretions and lung tissue stretch, is associated with improved lung growth and development 8 . In human fetuses with CDH, neck dissection and clipping of the trachea, initially at hysterotomy and subsequently endoscopically, results in fetal lung growth. However, this technique has also been abandoned because of the associated high rate of preterm delivery and irreversible damage to the laryngeal nerve and trachea 4, 9 . In this paper we report the development and initial experience with a minimally invasive and reversible fetoscopic tracheal occlusion (FETO) with a balloon in the treatment of severe CDH (Figure 1) . The clinical application of FETO was preceded by extensive animal studies for the development of the technique and the demonstration that a detachable endoluminal balloon can be inserted endoscopically, that it changes shape to provide effective occlusion of the growing trachea, does not cause tracheal damage and can be removed prenatally by endoscopy 10 -14 . 
METHODS
This is
Criteria for tracheal occlusion and consent
The entry criteria for FETO are a singleton pregnancy with severe CDH in an otherwise anatomically and chromosomally normal fetus. For both left-and rightsided CDH it is necessary that there is intrathoracic herniation of the liver and the LHR at 26-28 weeks is < 1. For consistency, all ultrasound examinations are performed by the same specialists in each institution. All patients meeting these criteria are informed of the likely poor prognosis and they are offered the options of expectant management with postnatal care at a tertiary institution, termination of pregnancy (TOP) or intrauterine therapy by FETO. Those choosing to have FETO are requested to have their delivery at an institution with facilities for neonatal intensive care and pediatric surgery. Additionally, the patients are informed that unless there is intrauterine removal of the balloon it is essential that delivery is by Cesarean section and ex-utero intrapartum treatment (EXIT) for tracheoscopic retrieval of the balloon is carried out while the fetus remains attached to the placental circulation 15 .
Operative technique
The procedure is performed under general anesthesia or combined spinal-epidural anesthesia, with hyperbaric bupivacaine (8 mg) injected into the spinal space at the L3-L4 or L4-L5 interspace, or local anesthesia (Xylocaine  1%, up to 20 mL). For all three methods the mothers are prehydrated with lactated Ringer's solution (1000 mL) and receive perioperative tocolysis (nifedipine 20 mg b.i.d.), antibiotics (cefazolin 2 g i.v. 8-hourly) and gastric acid reductors (oral citrate, metoclopramide and ranitidine). In the case of general anesthesia, induction is performed with thiopental (5 mg/kg), succinylcholine (2 mg/kg), fentanyl (2 µg/kg) and muscle relaxation is maintained with vecuronium titrated by peripheral nerve stimulation. Anesthesia is maintained with 0.5 minimum alveolar concentration of cevoflurane or isoflurane in oxygen. In the cases of local or regional anesthesia, fentanyl (15 µg/kg) is also given to the fetus by intramuscular injection. Ultrasound examination is first performed to determine the fetal and placental position for optimal trocar insertion. When necessary the fetal position is altered, by gentle external manipulation, to achieve better access to the trachea and to allow trocar insertion in the upper half of the uterus. Once the desired position is achieved, pancuronium (0.2 mg/kg), atropine (20 µg/kg) and fentanyl (15 µg/kg) are given by ultrasound-guided intramuscular injection through a 20G or 22G needle, providing fetal anesthesia, immobilization and prevention of fetal bradycardia.
After sterile draping of the patient, a thin-walled, flexible Teflon  cannula (10 F or 3.3 mm, Performa, Cook, Strombeek Bever, Belgium), loaded with a purpose-designed pyramidal trocar (11650TG, Karl Storz, Tüttlingen, Germany), is inserted into the amniotic cavity through the abdominal and uterine walls and directed towards the fetal mouth. The trocar is then withdrawn and purpose-designed fetoscopic instruments are inserted. These include a slightly bent sheath of 10.0 F, loaded with a 1.2 mm 10 000 pixel fiber endoscope (11505 and 11605KA, Karl Storz) and the balloon occlusion system, consisting of a catheter loaded with a detachable gold valve balloon (GVB 16, Cathnet Science, Paris, France). This system was originally designed for interventional radiological procedures to occlude anomalous vessels. The fetoscopic sheath has another side connector to allow amnioinfusion with Hartmann's solution heated to body temperature, for clearing the operative field and improving visualization.
The endoscope is introduced into the fetal mouth and directed over the tongue in the midline by visualizing the raphe of the palate and uvula, to the pharynx, then the larynx with the epiglottis as a landmark and finally through the vocal cords to the trachea ( Figure 2) . The endoscope is then advanced to identify the carina and the catheter is positioned to deliver the balloon just above it. The balloon is inflated with isotonic Omniscan  (0.8 mL, Nycomed, Amersham, UK), which is a magnetic resonance imaging contrast agent. The amniotic fluid, which may be increased by pre-existing polyhydramnios or amnioinfusion, is restored to normal by draining through the cannula at the end of the procedure.
In the first 24 h after the procedure the patients are treated with bed rest, low molecular weight heparin, pain relief on demand, cefazolin and nifedipine. Ultrasound examination to confirm the endotracheal presence of the inflated balloon and to monitor the LHR and fetal growth are performed every 1-2 weeks. Whenever preterm delivery is anticipated a course of corticosteroids is administered.
Reversal of tracheal occlusion
The initial intention was that all patients would be delivered electively by Cesarean section at 37-38 weeks and the balloon would be removed by EXIT through a purpose-designed, double-flow tracheosocope. This is composed of a 2.0-mm rod lens endoscope, an inner sheath with a connector for lavage and another for insertion of 3 F forceps or needle, and a blunt tip outer sheath with several frontal side openings and an outflow connector (Karl Storz). The double-flow design allows for continuous irrigation of the tip of the sheath and simultaneous drainage of any fluids through the side openings of the outer sheath. The outer diameter of this instrument is 11 F.
It was subsequently thought appropriate to remove the balloon prenatally at around 34 weeks, either by fetal tracheoscopy, in a manner described as for placement of the balloon and using 1-mm forceps under tracheoscopic vision, or by puncturing the balloon with an ultrasound-guided 20G needle, inserted through the maternal abdomen and directed to the fetal trachea through the fetal thorax.
In patients presenting in advanced labor or very preterm vaginal delivery is undertaken and the balloon is removed by tracheoscopy after clamping of the umbilical cord and the injection of pancuronium (0.2 mg/kg) and fentanyl (15 µg/kg) into the umbilical vein. Alternatively the balloon is punctured by means of a 20G needle inserted through the neck in the midline just under the cricoid cartilage.
Postnatal management
Postnatal surgery is delayed until after the condition of the infant is stabilized by such measures as neonatal endotracheal intubation and mechanical ventilation, surfactant administration, use of high-frequency oscillatory ventilation, inhaled nitric oxide for refractory pulmonary hypertension, and ECMO (extracorporeal membrane oxygenation) when necessary.
RESULTS
Fetal surgery
In this study we report the results from FETO in the first 21 cases that were treated between April 2002 and October 2003 (Table 1 ). There were 15 cases of left-and six of right-sided CDH. In the first two cases FETO was performed in the third trimester with the intention of performing emergency Cesarean section should there be any intraoperative complications. These cases demonstrated the feasibility of FETO and the improvement in LHR after surgery. However, both babies died of pulmonary hypoplasia within 36 h of birth and this was thought to be the consequence of the delayed tracheal occlusion. All subsequent procedures were carried out at 25-29 (median, 26) weeks.
In the early part of the study FETO was performed under general anesthesia but subsequently combined spinal epidural or local anesthesia was used. Endotracheal placement of the balloon was successfully performed in all 21 cases and the mean duration of the operation was 20 (range, 5-54) min. Correct placement of the balloon was achieved at the first tracheoscopy in 16 cases. In four cases the first balloon was placed too high or too low within the trachea and after removal with forceps a new balloon was inserted in the correct position during the same operation. In another case the first balloon was inflated in the right main stem bronchus, which caused a laceration. The balloon was withdrawn and the procedure was successfully repeated 2 weeks later when complete mucosal repair was observed.
Postoperative course
There were no maternal complications such as hemorrhage, placental abruption or pulmonary edema and none Table 1 Data on 21 consecutive fetuses undergoing fetal tracheal occlusion (FETO), including the side of diaphragmatic hernia, gestation at FETO and preoperative fetal lung area to head circumference ratio (LHR), method of anesthesia, the LHR 2 weeks after FETO (or shortly before delivery in those patients delivering within 2 weeks), incidence and gestation of prelabor amniorrhexis, gestation at delivery and interval between FETO and delivery, timing of removal of the endotracheal balloon, birth weight, duration of stay in the neonatal intensive care unit and outcome of the patients required additional tocolysis. However, in 11 (52.4%) patients there was postoperative prelabor amniorrhexis, which occurred within 2 weeks in five patients and after 2 weeks in six patients. Ultrasound scans after FETO demonstrated an increase in the echogenicity of the lungs within 48 h and an improvement in the LHR from a median of 0.7 (range, 0.4-0.9) before FETO to 1.8 (range, 1.1-2.9) within 2 weeks following surgery.
Operation
Reversal of tracheal occlusion
In seven of the first 10 cases the balloon was removed by EXIT. However, in patients delivering very prematurely it was decided to avoid Cesarean section and the balloon was either removed tracheoscopically or punctured immediately after vaginal delivery. In the second phase of the study the balloon was removed prenatally at 33-36 (median, 34) weeks in nine of the 11 cases, either by fetal tracheoscopy (n = 7) or by ultrasound-guided puncture (n = 2).
Neonatal outcome
The median gestational age at delivery was 34 (range, 27-38) weeks and in 17 (77.3%) patients this occurred after 32 weeks. Nine babies died in the neonatal period due to complications from pulmonary hypoplasia. Surgical repair of the CDH was carried out in 12 babies and in all but one of these (Case 13, Table 1 ) the defect was extensive and required the insertion of a patch. Two of these babies subsequently died, including one with pulmonary hypoplasia and another with good lung function but liver failure in association with a deletion in chromosome 8 that was missed at prenatal karyotyping (Case 7, Table 1 ). The 10 surviving babies at the time of writing were aged 6-25 (median, 18) months and were developing normally.
Survival was 30% in the first group of 10 fetuses and 63.6% in the second group of 11 fetuses. The total number of cases was too small for definite conclusions to be drawn as to the causes of this apparent improvement in survival. Nevertheless, improved survival coincided with a shift in the timing of FETO from the third to the second trimester, the administration of epidural rather than general anesthesia, reduced incidence of postoperative amniorrhexis and a change in the policy on the timing of removal of the balloon from the intrapartum to the prenatal period.
Contemporary controls
During the same period of study there were 17 cases examined in the participating centers that met the criteria for FETO but which declined prenatal therapy. In all cases there was isolated left-sided CDH with liver in the thorax and LHR of 0.43-0.98 (mean, 0.7). In five cases the parents elected for TOP and in 12 cases expectant management. In these 12 cases all babies were liveborn but 11 died in the neonatal period due to pulmonary hypoplasia and hypertension and only one (8.3%) baby survived and was discharged from hospital.
In addition to the above 17 cases, we examined 37 other cases with isolated CDH that did not fulfil our entry criteria for FETO either because the LHR was ≥ 1 (n = 24) or the liver was not in the thorax (n = 13). There were three TOPs, one fetal death and 33 live births, including 11 that died in the neonatal period and 22 (66%) that survived to discharge from hospital. Therefore, in the total series of 54 cases of isolated CDH that did not undergo FETO there were 45 live births and 23 (51%) of these survived to discharge from hospital.
DISCUSSION
This report demonstrates the feasibility of fetal surgery in severe CDH by a minimally invasive technique. Single-port, percutaneous endoscopy was used to achieve sustained and reversible FETO. The procedure, which appears to be safe for the mother, resulted in expansion of the fetal lungs and healthy survival in a substantial proportion of fetuses thought to have lethal CDH.
The selection criteria of liver herniation and LHR < 1 are widely accepted indicators of CDH that is likely to be lethal. This was confirmed by the findings in our contemporary controls, where the survival rate with expectant prenatal management was less than 10%. Furthermore, the data from the controls demonstrate that currently in fetuses with prenatally diagnosed and apparently isolated CDH the parents often elect to undergo TOP and in those patients electing expectant management the overall survival rate is about 50%.
This study demonstrates the evolution of a new technique in fetal surgery during the first phase of its introduction into clinical practice. Human fetal surgery was preceded by extensive animal studies demonstrating that first, obstruction of the trachea improves lung growth and development; second, effective and sustained obstruction can be achieved endoscopically through a detachable balloon with no damage to the trachea; and third, intrauterine reversal of the obstruction allows in-utero lung recovery and improves surfactant production 10 -14 . The need for the development of a technique that minimizes risks to the mother and potential damage to the fetus was stimulated by the results of previous methods of prenatal surgery in human fetuses with CDH 4, 7, 9 . In the first part of our study we used general anesthesia to optimize the operative conditions. After the initial experience demonstrating the feasibility of the technique and the short duration of the procedure we successfully adopted epidural or local anesthesia. Similarly, there was an evolution from undertaking surgery in the third trimester, with the rationale that emergency Cesarean delivery could be performed should there be any intraoperative complications, to 26 weeks, with the expectation that earlier intervention would improve lung growth and development. Additionally, the initial intention was to remove the balloon by EXIT. Subsequently, it became apparent that the balloon could be removed prenatally, either by fetoscopy or ultrasound-guided puncture. This avoided the need for delivery by Cesarean section of babies with a high risk of neonatal death and the burdens of intrapartum removal and delivery in highly specialized centers. In patients presenting in labor before removal of the balloon it would still be necessary to undertake ultrasoundguided intrapartum puncture or tracheoscopic removal at delivery.
An important complication of FETO is amniorrhexis and subsequent early preterm delivery. In our series using a percutaneous approach with a 3.3-mm cannula, 52% of cases had amniorrhexis. In a study by Harrison et al. 16 , in which tracheal occlusion was achieved after general anesthesia, laparotomy and uterine puncture with at least one instrument of > 5 mm, amniorrhexis occurred in all 11 cases examined. Although the number of cases we examined here is too small for definite conclusions to be drawn, it appears that the incidence of amniorrhexis decreased with experience in performing the technique. Nevertheless, it is unlikely that this problem can be eliminated and we are now exploring the feasibility of prophylactic amniopatch 17, 18 . Similarly, we are investigating further the selection of patients who may benefit from fetal surgery and the optimal timing and duration of tracheal occlusion before undertaking a randomized study to determine the potential value of FETO in the management of fetuses with isolated severe CDH.
